Drug-Resistant TB, Leprosy & Atypical Mycobacteria
What happens when the two best tuberculosis drugs stop working — because a patient couldn't finish their treatment? The answer is drug-resistant TB, a slow-motion catastrophe requiring years of harsh, toxic drugs. And the same family of stubborn, waxy-walled bacteria causes two other ancient scourges — leprosy and the infections that stalk the immunocompromised — each demanding, once again, a long combination of drugs.
A patient with tuberculosis begins to feel better after a few weeks and, understandably, stops taking his pills. Months later the infection roars back — but now the two most powerful drugs no longer work, because the interrupted treatment selected for resistant bacteria. He now faces multidrug-resistant TB: a year or more of second-line drugs, more toxic and less effective, with a much harder road to cure. This is the human cost of not finishing treatment, and it's why the mycobacteria demand such relentless discipline.
When the first-line drugs fail
Resistant TB is largely a man-made problem. Multidrug-resistant TB (MDR-TB) is defined as tuberculosis resistant to at least isoniazid AND rifampin — the two most important first-line drugs. It usually arises from incomplete, interrupted, or inadequate treatment, which lets resistant mutants take over. Treating it means abandoning the simple RIPE regimen for a longer, more toxic combination of second-line drugs: fluoroquinolones (moxifloxacin, levofloxacin), newer agents such as bedaquiline and pretomanid, and linezolid, among others. Extensively drug-resistant TB (XDR-TB) resists even some of these second-line drugs, narrowing the options further and worsening the outlook. The whole grim picture is a monument to why finishing treatment matters: every incomplete course is a chance for resistance to be born.
Leprosy: an ancient disease, still curable
Leprosy (Hansen's disease), caused by a slow-growing mycobacterium, is one of the oldest diseases known — and, like TB, it's treated with a long multidrug combination to prevent resistance. The core drugs are dapsone, rifampin, and clofazimine, given together for months to years depending on how many bacteria are present. Dapsone works like a sulfonamide by blocking folate synthesis, and shares sulfa's dangers — it can cause haemolysis in G6PD deficiency and methaemoglobinaemia. Clofazimine has a memorable side effect: it discolours the skin a reddish-brown to black. Leprosy treatment can also trigger inflammatory 'reactions' as the immune system responds to dying bacteria, sometimes needing steroids or thalidomide. The reassuring headline is that this once-feared, disfiguring disease is now fully curable with drugs.
The atypical mycobacteria
Beyond TB and leprosy, a group of 'nontuberculous' or atypical mycobacteria lives in the environment and usually only causes disease in people with weakened defences. The most important is Mycobacterium avium complex (MAC), which strikes patients with advanced HIV and other immunosuppression, causing disseminated infection. It's treated — again — with a combination: a macrolide (azithromycin or clarithromycin) plus ethambutol, often with rifabutin, and azithromycin can be given to prevent it in the most vulnerable. The unifying lesson across this whole family is simple and relentless: mycobacteria, with their waxy walls and slow, hidden growth, always demand several drugs together, given for a long time.
- MDR-TB = resistant to isoniazid + rifampin; arises from incomplete treatment; needs toxic second-line drugs.
- Second-line: fluoroquinolones, bedaquiline, linezolid; XDR-TB resists even some of these.
- Leprosy: dapsone + rifampin + clofazimine (long); dapsone → G6PD haemolysis; clofazimine → skin discoloration.
- MAC (atypical) hits the immunocompromised → macrolide + ethambutol (± rifabutin); azithromycin prophylaxis.
- All mycobacteria need multidrug therapy for a long time.
MDR-TB is the resistance chapter's grimmest real-world proof. Remember that resistant mutants pre-exist in a large bacterial population and that combination therapy exists to smother them. When a patient stops treatment early, the susceptible bacteria die but the few resistant ones survive and repopulate — and the next infection is untreatable by the best drugs. It's why adherence and directly-observed therapy matter so much in TB: incomplete treatment doesn't just fail the patient, it manufactures a harder disease for everyone.
- Stopping TB treatment early when feeling better. It breeds MDR-TB.
- Treating MDR-TB like ordinary TB. It needs a tailored second-line regimen.
- Giving dapsone to a G6PD-deficient patient without awareness of haemolysis.
- Using single-drug therapy for leprosy or MAC. Mycobacteria always need combinations.
Multidrug-resistant TB (MDR-TB) is defined as resistance to at least:
- MDR-TB (resistant to isoniazid + rifampin) arises from incomplete treatment; needs toxic second-line drugs.
- Leprosy: dapsone + rifampin + clofazimine — long, now fully curable.
- MAC (atypical) hits the immunocompromised → macrolide + ethambutol (± rifabutin).
- All mycobacteria demand multidrug therapy for a long time — adherence prevents resistance.
- Katzung BG. Basic & Clinical Pharmacology — Antimycobacterial Drugs (resistant TB, leprosy, atypicals).
- WHO — Guidelines on drug-resistant TB & leprosy multidrug therapy.
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Chemotherapy of tuberculosis, leprosy & MAC.
- Rang HP, Dale MM, et al. Rang & Dale's Pharmacology — Antimycobacterial agents.
- Whalen K. Lippincott Illustrated Reviews: Pharmacology — Drugs for leprosy & atypical mycobacteria.
